Better treatment option in mirabegron-solifenacin combination and their monotherapies.
- Conditions
- Health Condition 1: N328- Other specified disorders of bladder
- Registration Number
- CTRI/2023/10/058595
- Lead Sponsor
- Dr Muhammed Munavvir
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
OAB symptoms since 3 weeks
1 week drug free period for OAB treatment (mirabegron remains 5-6 days to be completely eliminated from the body [18])
Newly diagnosed OAB patient
Patients of both gender
Known case of Pregnant and lactating women
Neurogenic bladder
Patient with significant stress/ urge
UTI, prostatis, interstitial cystitis, bladder stone, malignant pelvic disease
Urinary retention
End Stage Renal Disease
Diabetic nephropathy
Uncontrolled Hypertension[14] (Systolic pressure =180mmHg and diastolic pressure =110mmHg)
Study & Design
- Study Type
- PMS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.